Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists. - Wikidata - awgldk - TriplyDB

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

http://www.wikidata.org/entity/Q37066113

about

Improved variants of SrtA for site-specific conjugation on antibodies and proteins with high efficiency Stable and Potent Selenomab-Drug Conjugates.Introducing Glycolinkers for the Functionalization of Cytotoxic Drugs and Applications in Antibody-Drug Conjugation Chemistry.Insights from native mass spectrometry approaches for top- and middle- level characterization of site-specific antibody-drug conjugates.Bioconjugation - using selective chemistry to enhance the properties of proteins and peptides as therapeutics and carriers.Cancer-Associated, Stimuli-Driven, Turn on Theranostics for Multimodality Imaging and Therapy.Development of a facile antibody-drug conjugate platform for increased stability and homogeneity Rapid formation of a stable boron-nitrogen heterocycle in dilute, neutral aqueous solution for bioorthogonal coupling reactions.DNA Microcapsule for Photo-Triggered Drug Release Systems.Site-Selective Labeling of Native Proteins by a Multicomponent Approach.Fn3 proteins engineered to recognize tumor biomarker mesothelin internalize upon binding.Glutamic acid-valine-citrulline linkers ensure stability and efficacy of antibody-drug conjugates in mice.Antibody drug conjugates (ADCs) charged with HDAC inhibitor for targeted epigenetic modulation Online SERS Quantification ofStaphylococcus aureusand the Application to Diagnostics in Human Fluids

P2860

Q37184808-0D78ED51-7490-4A90-944E-7F39F61AEB32 Q38432502-A725042F-9323-4620-9F80-D2C4094ADC4C Q38736346-75D9E67E-219C-4E3C-8F63-BFF451914E63 Q38838739-079B4491-DC7A-4483-9E9C-AACBB60A0E80 Q38909537-6CE02A22-846A-4E2E-BC91-FBA473CDB6C4 Q39216032-738D23B0-0D31-44D2-8B09-A53EAB1939DB Q42293596-D4E07BF7-1ACC-4249-A034-BA507326621F Q43165833-520E946C-8FC9-4D63-ABC6-86298AB3E51C Q47632277-A16FAD67-E8E8-4620-9147-5F6C69B8A15D Q48263109-BB757AC2-AC74-4323-BB21-0B9F91C539A5 Q55257427-1CCF0A62-6EC6-4B81-81C6-8D1EF08CF900 Q55385806-2D6C58F6-72AB-44E0-828E-87003369DBB7 Q57139824-6280A43C-9164-40D6-900C-A0583242A2F1 Q58386243-5A887604-9664-437F-9465-7EB3E1B2E83A

P2860

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

http://www.wikidata.org/entity/Q37066113

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 26 August 2015

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

@en

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

@nl

type

label

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

@en

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

@nl

prefLabel

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

@en

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists.

@nl

P1433

Q37066113-93026929-4396-4526-8A46-0AC8A7E98CA8

P1476

Q37066113-9482DD58-6E01-4CAE-AF36-D06B3FE5C81E

P2093

Q37066113-1FA740DF-1901-44FF-A249-52A9D8C98D39

Q37066113-80DDDBD6-C5AA-4161-A064-820684698687

Q37066113-B2AABEEB-2C5A-4F68-8651-FD0325E525AB

Q37066113-F64231BC-CBCD-49F8-9D38-AC1EC6577E64

P2860

Q37066113-02BDE2B5-17A4-44C5-87C0-AA649731BEAA

Q37066113-06595E19-0931-4C6E-AC9E-DD522ED778B7

Q37066113-06E11714-752D-4A4C-A6D4-18F47B798E7E

Q37066113-0FF3437A-5353-42A5-9005-97683381F3E0

Q37066113-106F8227-518C-48D7-B3E5-61590BC85F32

Q37066113-1338126A-958D-4931-80E5-D1FFD3C13BB6

Q37066113-16149B2C-1FC4-4418-BB39-34CEBCA6187C

Q37066113-1632B341-5373-4988-B76C-F9004886BEB5

Q37066113-1F980370-5713-4561-A493-22958159FB98

Q37066113-1FC8C7A3-30E0-4090-83B3-5EF4588DA744

P304

Q37066113-E9305279-D1C7-4D7A-A750-A9013C274E41

P31

Q37066113-853055F2-D268-4F9A-9146-33393206EEAE

P356

Q37066113-F989ACA1-79C8-4D70-8846-5E0B360E8299

P433

Q37066113-F4034415-CBCB-41FA-B909-B17D7B8C6E80

P478

Q37066113-20D23764-4C00-47A2-8C74-4424B530A009

P50

Q37066113-D7CF0F2D-249F-4117-9660-0981018B786F

Q37066113-DA554D41-2D3F-4CFC-B8B2-56C946047B4A

P577

Q37066113-A75D5B90-9396-4C84-A96A-0A91787978A1

P5875

Q37066113-B2BF3451-8B3B-483A-BB2C-966480CB73C6

P698

Q37066113-FCA24DEF-6E3B-4CB6-A4EE-0765408ED22E

P921

Q37066113-43F05E59-D8D2-4F55-BA40-D57DF3F91800

P932

Q37066113-AFFDFD70-CAF8-40F6-ABA4-3ADEC2BF1525

P356

ACS.BIOCONJCHEM.5B00399

P1433

Bioconjugate Chemistry

P1476

Field Guide to Challenges and Opportunities in Antibody-Drug Conjugates for Chemists

@en

P2093

Barbara Osborne

http://www.w3.org/2001/XMLSchema#string

Jiaming Zhuang

http://www.w3.org/2001/XMLSchema#string

Mallory R Gordon

http://www.w3.org/2001/XMLSchema#string

Mine Canakci

http://www.w3.org/2001/XMLSchema#string

P2860

Strictosidine synthase: mechanism of a Pictet-Spengler catalyzing enzyme

Synthesis of site-specific antibody-drug conjugates using unnatural amino acids

Polymer nanogels: a versatile nanoscopic drug delivery platform

Trastuzumab emtansine for HER2-positive advanced breast cancer.

Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia

A strain-promoted [3 + 2] azide-alkyne cycloaddition for covalent modification of biomolecules in living systems

Protein reactions with methyl and ethyl vinyl sulfones

Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin).

N-terminal labeling of proteins by the Pictet-Spengler reaction.

Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy.

P304

2198-2215

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1021/ACS.BIOCONJCHEM.5B00399

http://www.w3.org/2001/XMLSchema#string

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

26

http://www.w3.org/2001/XMLSchema#string

P50

P577

2015-09-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

281342995

http://www.w3.org/2001/XMLSchema#string

P698

26308881

http://www.w3.org/2001/XMLSchema#string

P921

P932

4933296

http://www.w3.org/2001/XMLSchema#string